Rest of World Factor VIII Deficiency Treatment Market Analysis Report talks about the growth rate till 2027 of manufacturing process, growth, key factors driving this market with sales analysis Global Factor VIII Deficiency Treatment, revenue and prices of Rest of the world major manufacturers, distributors, traders and dealers.
Coherent Market Insights always aims to provide its clients with in-depth analysis and the best research material from different markets. The “rest of the world factor VIII deficiency treatment market is expected to develop with increasing expansion prospects”. The Rest of the World Factor VIII Deficiency Treatment Market report presents a calculated opinion of the analyzed data of the Rest of the World Factor VIII Deficiency Treatment market. It explains various opportunities dedicated to different industries, suppliers, organizations and associations offering various products and services, for example offering them specific advice for their expansion in the competition for reliable services to consumers. The report provides in-depth information about major market competitors and emerging companies holding significant market share based on demand, revenue, sales, high quality product manufacturers, and service providers.
The major players in the Factor VIII Deficiency Treatment Market from the rest of the world are The VIII deficiency treatment market includes Baxter International, Inc., Biogen, Inc., Bayer AG, CSL Behring, Ferring BV, F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion and Novo Nordisk A / S.
During the forecast period, the rest of the global factor VIII deficiency treatment market is expected to increase owing to an increase in the incidence and prevalence of hemophilia. According to 2018 World Federation of Hemophilia (WFH) figures, there were approximately 440,000 people worldwide with hemophilia, with approximately 173,000 people diagnosed with hemophilia A or B in 2017.
Due to the growing need for therapy for factor VIII deficiency, major players are focusing on product or drug releases and approvals. The FDA approved Kedrion’s double viral inactivated anti-hemophilic factor Koate (DVI) with Mix2Vial for the treatment of factor VIII deficiency in March 2016. Additionally, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary from the Roche Group, has published HEMLIBRA, a humanized, anticoagulant, factor X, factor VIII, bio-specific monoclonal antibody for routine prophylaxis to prevent or mitigate bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) which are taking factor VIII inhibitors.
Buy this full activity report at a discount of US $ 2000 @
Due to the favorable regulatory scenario and guidance from government authorities, Asia-Pacific is expected to provide attractive business opportunities in the rest of the global factor VIII deficiency treatment market during the forecast period, which is expected to accelerate the uptake of factor VIII deficiency treatment. market growth during the forecast period. According to the 2015 study by the World Hemophilia Foundation on national tenders for the purchase of clotting factor concentrates, the Brazilian Agency for Health Surveillance (ANVISA), which is the national authority control and inspection of products, the purchase of clotting factor concentrates in Brazil must be authorized and approved by the Brazilian Agency for Health Surveillance (ANVISA).
In addition, several key market players are focusing on partnerships for the purpose of developing novel therapies for the treatment of deficiency, which is expected to promote the market growth during the forecast period. RCSI, a Dublin-based international health sciences agency, and Bayer AG announced a scientific partnership in August 2018 to explore alternative treatment strategies for people with extreme hemophilia. Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer Inc. announced a global partnership and license agreement in May 2017 for the production and commercialization of a gene therapy-based drug for the treatment of hemophilia A.
Key points to remember
Due to the increase in hemophilia cases and new product and drug approvals and launches, the rest of the global factor VIII deficiency treatment market is expected to grow at a CAGR of 4.7% during the period forecast. According to the 2018 National Hemophilia Foundation survey, one in 10,000 people are born with hemophilia A due to clotting factor VIII deficiency, and one in 50,000 people are born with hemophilia B due to coagulation factor IX deficiency.
Due to its cost effectiveness, the plasma-bound coagulation factor concentrates segment dominated the factor VIII deficiency drug market in 2018. According to studies released by the World Federation of Hemophilia in 2016, the demand for coagulation factors derived from plasma is higher than that of recombinant coagulation concentrates. , because of its ease of distribution in developing economies and its low costs.
Major companies contributing to the rest of the global factor VIII deficiency treatment market are CSL Behring, Bayer AG, Biogen, Inc., Kedrion, Baxter International, Inc., Novo Nordisk A / S, Pfizer, Inc., F. Hoffmann -La Roche AG and Ferring BV
Key Highlights of the Rest of the World Factor VIII Deficiency Treatment Market Report Table of Contents
Chapter 1 Industry Overview
1.3 Scope of the research
1.4 Market Analysis by Regions
1.5 Rest of the World Factor VIII Deficiency Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Impact on Factor VIII Deficiency Treatment Industry in the Rest of the World
Chapter 2 Global Factor VIII Deficiency Treatment Competition in Rest of World by Types, Applications and Major Regions and Countries
2.1 Global Factor VIII Deficiency Rest of World Treatment (Volume & Value) by Type
2.3 Global Factor VIII Deficiency Treatment in Rest of World (Volume & Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional production market analysis
Chapter 4 Global Sales, Consumption, Export, Import of Global Factor VIII Deficiency Treatment by Regions (2016-2021)
Chapter 5 North America and Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 6 East Asia and Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 7 Europe Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 8 Southeast Asia and Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 9 Southeast Asia and Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 10 Middle East & Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 11 Africa Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 12 Oceania Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 13 South America Rest of the World Factor VIII Deficiency Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures of the Factor VIII Deficiency Treatment Industry in Rest of the World
Chapter 15 Global Factor VIII Deficiency Treatment Market Forecast in Rest of World (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients from all walks of life, from Fortune 500 companies to nonprofits and startups looking to gain a foothold in the market. We excel in delivering unmatched actionable business insights across a variety of industry verticals, including chemicals & materials, healthcare, food & beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837